Publikationen zum Thema Tumorerkrankungen

Cell-free plasma DNA for disease stratification and prognosis in head and neck cancer.

Schirmer MA, Beck J, Leu M, Oellerich M, Rave-Fränk M, Walson PD, Schütz E, Canis M.

Clin Chem 2018; 64(6): 959–970. doi: 10.1373/clinchem.2017.285668

Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy.

Weiss GJ, Beck J, Braun DP, Bornemann-Kolatzki K, Barilla H, Cubello R, Quan W, Sangal A, Khemka V, Waypa J, Mitchell WM, Urnovitz H, Schütz E.

Clin Cancer Res. 2017 23(17):5074-5081. doi: 10.1158/1078-0432.CCR-17-0231. Epub 2017 Mar 20.

PMID: 28320758

Circulating Cell-Free DNA—Diagnostic and Prognostic Applications in Personalized Cancer Therapy

Michael Oellerich, Ekkehard Schütz, Julia Beck, Philip D. Walson.

Therapeutic Drug Monitoring: April 2019 - Volume 41 - Issue 2 - p 115–120; doi: 10.1097/FTD.0000000000000566.

Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma.

Weiss GJ, Blaydorn L, Beck J, Bornemann-Kolatzki K, Urnovitz H, Schütz E, Khemka V.

Invest New Drugs. 2017 Nov 8. doi: 10.1007/s10637-017-0525-1.

PMID: 29119276

Using Circulating Cell-free DNA to Monitor Personalized Cancer Therapy.

Oellerich M, Schütz E, Beck J, Kanzow P, Plowman NP, Weiss GJ, Walson PD.

Crit. Rev. Clin. Lab. Sci 2017; 54:205-218. doi: 10.1080/10408363.2017.1299683.

PMID: 28393575

Liquid Biopsies in Lung Cancer: Four Emerging Technologies and Potential Clinical Applications.

Chudasama D, Katopodis P, Stone N, Haskell J, Sheridan H, Gardner B, Urnovitz H, Schütz E, Beck J, Hall M, Barr J, Sisu C, Rice A, Polychronis A, Anikin V, Karteris E.

Cancer (Basel). 2019 Mar 7;11(3).pii: E331. doi: 10.3390/cancers11030331.

Chromosomal instability in cell-free DNA is a serum biomarker for prostate cancer.

Schütz E, Akbari MR, Beck J, Urnovitz H, Zhang WW, Bornemann-Kolatzki K, Mitchell WM, Nam RK, Narod SA.

Clin Chem. 2015 Jan;61(1):239-48. doi: 10.1373/clinchem.2014.226571.

PMID: 25348670

Genome aberrations in canine mammary carcinomas and their detection in cell-free plasma DNA.

Beck J, Hennecke S, Bornemann-Kolatzki K, Urnovitz HB, Neumann S, Ströbel P, Kaup FJ, Brenig B, Schütz E.

PLoS One. 2013 Sep 30;8(9):e75485. doi: 10.1371/journal.pone.0075485.

PMID: 24098698

Next generation sequencing of serum circulating nucleic acids from patients with invasive ductal breast cancer reveals differences to healthy and nonmalignant controls.

Beck J, Urnovitz HB, Mitchell WM, Schütz E.

Mol Cancer Res. 2010 Mar;8(3):335-42. doi: 10.1158/1541-7786.MCR-09-0314.

PMID: 20215424

Profile of the circulating DNA in apparently healthy individuals.

Beck J, Urnovitz HB, Riggert J, Clerici M, Schütz E.

Clin Chem. 2009 Apr;55(4):730-8. doi: 10.1373/clinchem.2008.113597.

PMID: 19181738

Plasma EGFR mutation testing in non-small cell lung cancer: A value proposition

Michael Oellerich, Robert H. Christenson, Julia Beck, Philip D. Walson

Clin Chim Acta. 2019 May 21;495:481-486. doi: 10.1016/j.cca.2019.05.019.

PMID: 31125533  DOI: 10.1016/j.cca.2019.05.019